Fig. 1From: Discriminating phenotypic signatures identified for tocilizumab, adalimumab, and tofacitinib monotherapy and their combinations with methotrexateBioMAP profiles. a BioMAP profiles for all agents, b individual profile for tocilizumab, c clustering analysis of all agents at all concentrations, and d clustering analysis of other inhibitors (infliximab, etanercept, certolizumab, ruxolitinib, tofacitinib, and baricitinib)Back to article page